US Stem Cell Inc (USRM)

[TheHungryHippo]

IMPORTANT READ: FORM 4'S "THE BUYOUT RUMORS" of USRM $$$$$$$$$$$$$

HERE IS EVIDENCE OF WHY I THINK THERE IS A BUYOUT CURRENTLY PENDING ON $USRM, AND BELIEVE ME- IM NOT THE ONLY ONE WHO THINKS THIS!!!!! READ:

In August 2016, A disagreement by the board of directors over % of ownership, led to a court case between the Board of Directors of USRM; The case was about ownership, not monetary damages.

in the Broward Co. Florida Pacer Filings, there was a footnote THAT BEGAN THE RUMORS THAT BIG PHARMA WAS ACTIVELY ENGAGED IN BUYOUT NEGOTIATIONS WITH $USRM



The Case ended up being SETTLED, and disposed of...

Demonstrating a progressive step forward, Knutson joins the Board of Directors just as the two companies amicably settled a legal dispute related to NorthStar’s preferred shares.

OFFICIAL SCREENSHOT OF BROWARD CO. COURT PACER FILINGS:


But, along with the footnotes commenting on How CEO Tomas tried to sell the company multiple times...

After the Settlement- we learned this;

THEY STRUCK A DEAL.

NORTHSTAR, WHICH IS A CONGLOMERATE OF THE BOARD OF DIRECTORS:

-Which was formed as an ownership holdings company for the BOD members who invested in USRM throughout the years with their own personal money; Members Include,

1. Dr. William P. Murphy; Current Chairman of the Board (Sold Cordis to J&J for 1.9 Billion)
2. Dr. Samuel Ahn - Dallas Cardio Surgeon, Original investor in funding USRM during many years
3. Gregory Knutson- Investor that replaced Charles Hart as Managing Director of Northstar
4. Mike Tomas - The Current CEO.
5. Kristin Comella - The Chief Scientific Officer, and Worldwide Leader in Stem Cell Research


USRM THE COMPANY, CEO, and The other BOD Members Agreed to the following:

1. The argument about preferred shares, was settled.

2. More common shares and ownership percentage to Northstar Biotech Group LLC

3. Greg Knutson Becomes a new Board Member,

4. CEO of USRM Mike Tomas, and CSO Kristin Comella- Each Become 5% owners of Northstar Biotech Group LLC

5. THEY AGREED THAT 10% OF ALL INTERNATIONAL SALES- would be granted to Northstar Biotech Group LLC

THIS AGREEMENT WAS FINAL AND REACHED AND SETTLED UPON- MARCH 1ST, 2017

OFFICIALLY.

MY Speculation;

Now why would they need to argue in mediation, and agree upon securing royalties for 10% of international sales if they did not expect to be making HUGE MONEY, and they know that MYOCELL would eventually become commercialized?

In my opinion, thats what this is about. MYOCELL has the potential to generate MILLIONS AND MILLIONS of dollars in PROFITS- WORLDWIDE.$$$$$$$$$$$$

FIRST CORRESPONDENCE:


SECOND CORRESPONDENCE:





The Financials of USRM include clauses about how they can IMMEDIATELY VEST- THEIR OPTIONS IN THE EVENT OF "AN ACCELERATION EVENT"



Options WILL Accelerate upon a Change of Control: when a change of control occurs, the unvested portion of the options automatically and immediately vests. These provisions enable the optionee to exercise all of the options, and obtain a portion of the merger consideration, whether such consideration consists of cash or stock.

DEFINE: ACCELERATION EVENTS
https://www.cooleygo.com/what-is-double-trigger-acceleration-and-how-does-it-work/



AND JUST HOW MANY OPTIONS AND FORM 4'S ARE THERE?

Well. ... every single Northstar Board Member owns the right to immediately purchase common shares:

AND SO DO THE OTHER TWO MEMBERS OF THE CURRENT BOD:

MARK P. BORMAN- He has raised $7.5 billion in 12 offerings to finance rapid growth, acquisitions and strategic transformations through leveraged buyouts, IPO and secondary equity offerings, convertible note offerings, and exits with spinoffs into three new IPO companies, which were subsequently acquired.

SHELDON ANDERSON- Another Advisor who sits on the board.

Read more about board members here:
http://us-stemcell.com/en/about-us/
















MY OPINION IS THIS:

THE COMPANY - SHOULD HAVE BEEN SOLD LAST YEAR & IN MY OPINION, but they got into a argument about who would get MORE MONEY!!!!!!!,

NOW THAT THE AGREEMENT OF 10% OF INTERNATIONAL SALES HAS BEEN REACHED: ALL WE ARE WAITING ON NOW IS THE FDA TO SAY : APPROVED!!!!!!! AND THEN IT WOULD MAKE PERFECT SENSE, THAT MULTIPLE BUYOUT OFFERS ARE CURRENTLY ON THE TABLE, AND PENDING FOR $USRM, BUT WITH FDA APPROVAL THE VALUATION WILL BE FAR HIGHER!!!!!!!!!!!!!!!!!

IF THE FDA APPROVES MYOCELL FOR FDA FAST TRACKING, THE VALUATION OF THE COMPANY: $USRM COULD POSSIBLY REACH IN AT A MINIMUM :

IN MY OPINION OF A MARKET VALUATION OF $500 MILLION DOLLARS.


CONSERVITIVELY.

$USRM